Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2017
[Treatment of speech disorders in preschool children].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shalimov V F, Suvorinova N Yu, Nesterovsky Yu E
Аннотация
AIM: To study the efficacy of neyroferon in developmental speech disorders (SDD).
MATERIAL AND METHODS: Thirty preschool children were stratified into 3 groups: 4-5 years (n=8), 5-6 years (n=10) and 6-7 years (n=12). The children were treated with neyroferon in dose 1 tablet three times a day during 2 month. A multifaceted study of speech disorders using several methods was conducted. General mental state, emotional and behavioral characteristics of the children were assessed as well.
RESULTS AND CONCLUSION: A therapeutic effect of neyroferon (the improvement of auditory-speech memory, expressive speech, phonemic perception, articulatory movements, vocabulary activity, connected speech etc) as well as the decrease in anxiety, hyperactivity and attention deficit was found in children with SDD. The safety of the drug was confirmed. The results should be treated as preliminary ones.
MATERIAL AND METHODS: Thirty preschool children were stratified into 3 groups: 4-5 years (n=8), 5-6 years (n=10) and 6-7 years (n=12). The children were treated with neyroferon in dose 1 tablet three times a day during 2 month. A multifaceted study of speech disorders using several methods was conducted. General mental state, emotional and behavioral characteristics of the children were assessed as well.
RESULTS AND CONCLUSION: A therapeutic effect of neyroferon (the improvement of auditory-speech memory, expressive speech, phonemic perception, articulatory movements, vocabulary activity, connected speech etc) as well as the decrease in anxiety, hyperactivity and attention deficit was found in children with SDD. The safety of the drug was confirmed. The results should be treated as preliminary ones.